Impact of Azelnidipine in reducing urinary albumin excretion and carotid atherosclerosis in type 2 diabetes patients: BOAT 2 study Review
Hypertension and Diabetes Mellitus are the global health burden and strong risk factors for coronary artery disease (1). Impaired glucose tolerance and insulin resistance are associated with hypertension which in turn leads to the development of diabetes in hypertensive patients. This causes inflammation which leads to atherosclerosis and thus leading to an increased risk of cerebrovascular and cardiovascular diseases. Coexistence of both hypertension and diabetes increases the risk of cardiovascular diseases by 2-3fold (2). The risk of these life- threatening diseases escalates with the presence of other complications like diabetic nephropathy.
There is a wide variety of anti-hypertensive drugs that are used to control blood pressure including calcium channel blockers, renin-angiotensin system inhibitors (angiotensin II receptor blockers [ARBs] and angiotensin-converting enzyme [ACE] inhibitors), diuretics and β-blockers. α-blockers and central sympathetic nerve inhibitors are also administered additionally (3). Various studies in the past have shown that renin-angiotensin system blockers delay the progression of diabetic nephropathy and hence are recommended as the primary antihypertensive drugs (4,5). But as monotherapy may not be sufficient for effective blood pressure control, Combination therapy with other drugs is used.
The above article has been published by Medical Dialogues under the MD Brand Connect Initiative. For more details on Azelnidipine, click here